Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Jul;74(1):86–91. doi: 10.1038/bjc.1996.320

Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections.

P Pfeiffer 1, P P Clausen 1, K Andersen 1, C Rose 1
PMCID: PMC2074610  PMID: 8679464

Abstract

The prognostic role of the epidermal growth factor receptor (EGFR) and the related receptor p185HER-2 in lung cancer is as yet undefined. We investigated the immunohistochemical expression of EGFR (monoclonal antibody R1; Amersham) and p185HER-2 (polyclonal antibody A485; Dako) in cryosections. A total of 186 unselected and systemically untreated patients with non-small-cell lung cancer (NSCLC) diagnosed and treated at Odense University Hospital, Denmark, were included. Median follow-up period was 66 months. EGFR and p185HER-2 was highly expressed in 55% and 26% of cases respectively. Expression of EGFR was independent of p185HER-2 expression. The expression of EGFR was higher in squamous cell carcinomas whereas the level of p185HER-2 staining was higher in adenocarcinomas. Expression of either or both receptors was not correlated with age, histological grading, stage and prognosis. We conclude that immunohistochemical detection of these growth factor receptors failed to demonstrate a prognostic significance in patients operated on for NSCLC.

Full text

PDF
89

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Altman D. G., Lausen B., Sauerbrei W., Schumacher M. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst. 1994 Jun 1;86(11):829–835. doi: 10.1093/jnci/86.11.829. [DOI] [PubMed] [Google Scholar]
  2. Berger M. S., Gullick W. J., Greenfield C., Evans S., Addis B. J., Waterfield M. D. Epidermal growth factor receptors in lung tumours. J Pathol. 1987 Aug;152(4):297–307. doi: 10.1002/path.1711520408. [DOI] [PubMed] [Google Scholar]
  3. Bolufer P., Lluch A., Molina R., Alberola V., Vazquez C., Padilla J., Garcia-Conde J., Llopis F., Guillem V. Epidermal growth factor in human breast cancer, endometrial carcinoma and lung cancer. Its relationship to epidermal growth factor receptor, estradiol receptor and tumor TNM. Clin Chim Acta. 1993 Apr 16;215(1):51–61. doi: 10.1016/0009-8981(93)90248-3. [DOI] [PubMed] [Google Scholar]
  4. Bongiorno P. F., Whyte R. I., Lesser E. J., Moore J. H., Orringer M. B., Beer D. G. Alterations of K-ras, p53, and erbB-2/neu in human lung adenocarcinomas. J Thorac Cardiovasc Surg. 1994 Feb;107(2):590–595. [PubMed] [Google Scholar]
  5. Cerny T., Barnes D. M., Hasleton P., Barber P. V., Healy K., Gullick W., Thatcher N. Expression of epidermal growth factor receptor (EGF-R) in human lung tumours. Br J Cancer. 1986 Aug;54(2):265–269. doi: 10.1038/bjc.1986.172. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Dazzi H., Hasleton P. S., Thatcher N., Barnes D. M., Wilkes S., Swindell R., Lawson R. A. Expression of epidermal growth factor receptor (EGF-R) in non-small cell lung cancer. Use of archival tissue and correlation of EGF-R with histology, tumour size, node status and survival. Br J Cancer. 1989 May;59(5):746–749. doi: 10.1038/bjc.1989.156. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Di Carlo A., Mariano A., Macchia P. E., Cecere C., Ferrante G., Macchia V. Epidermal growth factor receptor and lipid membrane components in human lung cancers. J Endocrinol Invest. 1993 Feb;16(2):99–107. doi: 10.1007/BF03347657. [DOI] [PubMed] [Google Scholar]
  8. Dittadi R., Gion M., Pagan V., Brazzale A., Del Maschio O., Bargossi A., Busetto A., Bruscagnin G. Epidermal growth factor receptor in lung malignancies. Comparison between cancer and normal tissue. Br J Cancer. 1991 Oct;64(4):741–744. doi: 10.1038/bjc.1991.390. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gazdar A. F. The molecular and cellular basis of human lung cancer. Anticancer Res. 1994 Jan-Feb;14(1B):261–267. [PubMed] [Google Scholar]
  10. Gorgoulis V., Aninos D., Mikou P., Kanavaros P., Karameris A., Joardanoglou J., Rasidakis A., Veslemes M., Ozanne B., Spandidos D. A. Expression of EGF, TGF-alpha and EGFR in squamous cell lung carcinomas. Anticancer Res. 1992 Jul-Aug;12(4):1183–1187. [PubMed] [Google Scholar]
  11. Gullick W. J. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull. 1991 Jan;47(1):87–98. doi: 10.1093/oxfordjournals.bmb.a072464. [DOI] [PubMed] [Google Scholar]
  12. Hendler F. J., Ozanne B. W. Human squamous cell lung cancers express increased epidermal growth factor receptors. J Clin Invest. 1984 Aug;74(2):647–651. doi: 10.1172/JCI111463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Holmes E. C. Postoperative chemotherapy for non-small-cell lung cancer. Chest. 1993 Jan;103(1 Suppl):30S–34S. doi: 10.1378/chest.103.1_supplement.30s. [DOI] [PubMed] [Google Scholar]
  14. Kaseda S., Ueda M., Ozawa S., Ishihara T., Abe O., Shimizu N. Expression of epidermal growth factor receptors in four histologic cell types of lung cancer. J Surg Oncol. 1989 Sep;42(1):16–20. doi: 10.1002/jso.2930420106. [DOI] [PubMed] [Google Scholar]
  15. Kern J. A., Schwartz D. A., Nordberg J. E., Weiner D. B., Greene M. I., Torney L., Robinson R. A. p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res. 1990 Aug 15;50(16):5184–5187. [PubMed] [Google Scholar]
  16. Kern J. A., Slebos R. J., Top B., Rodenhuis S., Lager D., Robinson R. A., Weiner D., Schwartz D. A. C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. J Clin Invest. 1994 Feb;93(2):516–520. doi: 10.1172/JCI117001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Kokai Y., Myers J. N., Wada T., Brown V. I., LeVea C. M., Davis J. G., Dobashi K., Greene M. I. Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts. Cell. 1989 Jul 28;58(2):287–292. doi: 10.1016/0092-8674(89)90843-x. [DOI] [PubMed] [Google Scholar]
  18. Prigent S. A., Lemoine N. R. The type 1 (EGFR-related) family of growth factor receptors and their ligands. Prog Growth Factor Res. 1992;4(1):1–24. doi: 10.1016/0955-2235(92)90002-y. [DOI] [PubMed] [Google Scholar]
  19. Ravdin P. M., Chamness G. C. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers--a review. Gene. 1995 Jun 14;159(1):19–27. doi: 10.1016/0378-1119(94)00866-q. [DOI] [PubMed] [Google Scholar]
  20. Richardson G. E., Johnson B. E. The biology of lung cancer. Semin Oncol. 1993 Apr;20(2):105–127. [PubMed] [Google Scholar]
  21. Rosell R., Gómez-Codina J., Camps C., Maestre J., Padille J., Cantó A., Mate J. L., Li S., Roig J., Olazábal A. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med. 1994 Jan 20;330(3):153–158. doi: 10.1056/NEJM199401203300301. [DOI] [PubMed] [Google Scholar]
  22. Roth J. A., Fossella F., Komaki R., Ryan M. B., Putnam J. B., Jr, Lee J. S., Dhingra H., De Caro L., Chasen M., McGavran M. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst. 1994 May 4;86(9):673–680. doi: 10.1093/jnci/86.9.673. [DOI] [PubMed] [Google Scholar]
  23. Rusch V., Baselga J., Cordon-Cardo C., Orazem J., Zaman M., Hoda S., McIntosh J., Kurie J., Dmitrovsky E. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res. 1993 May 15;53(10 Suppl):2379–2385. [PubMed] [Google Scholar]
  24. Shi D., He G., Cao S., Pan W., Zhang H. Z., Yu D., Hung M. C. Overexpression of the c-erbB-2/neu-encoded p185 protein in primary lung cancer. Mol Carcinog. 1992;5(3):213–218. doi: 10.1002/mc.2940050308. [DOI] [PubMed] [Google Scholar]
  25. Simon R., Altman D. G. Statistical aspects of prognostic factor studies in oncology. Br J Cancer. 1994 Jun;69(6):979–985. doi: 10.1038/bjc.1994.192. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Sobol R. E., Astarita R. W., Hofeditz C., Masui H., Fairshter R., Royston I., Mendelsohn J. Epidermal growth factor receptor expression in human lung carcinomas defined by a monoclonal antibody. J Natl Cancer Inst. 1987 Sep;79(3):403–407. [PubMed] [Google Scholar]
  27. Souquet P. J., Chauvin F., Boissel J. P., Cellerino R., Cormier Y., Ganz P. A., Kaasa S., Pater J. L., Quoix E., Rapp E. Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet. 1993 Jul 3;342(8862):19–21. doi: 10.1016/0140-6736(93)91882-m. [DOI] [PubMed] [Google Scholar]
  28. Tateishi M., Ishida T., Mitsudomi T., Kaneko S., Sugimachi K. Immunohistochemical evidence of autocrine growth factors in adenocarcinoma of the human lung. Cancer Res. 1990 Nov 1;50(21):7077–7080. [PubMed] [Google Scholar]
  29. Tateishi M., Ishida T., Mitsudomi T., Kaneko S., Sugimachi K. Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. Eur J Cancer. 1991;27(11):1372–1375. doi: 10.1016/0277-5379(91)90012-3. [DOI] [PubMed] [Google Scholar]
  30. Veale D., Ashcroft T., Marsh C., Gibson G. J., Harris A. L. Epidermal growth factor receptors in non-small cell lung cancer. Br J Cancer. 1987 May;55(5):513–516. doi: 10.1038/bjc.1987.104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Veale D., Kerr N., Gibson G. J., Harris A. L. Characterization of epidermal growth factor receptor in primary human non-small cell lung cancer. Cancer Res. 1989 Mar 1;49(5):1313–1317. [PubMed] [Google Scholar]
  32. Veale D., Kerr N., Gibson G. J., Kelly P. J., Harris A. L. The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. Br J Cancer. 1993 Jul;68(1):162–165. doi: 10.1038/bjc.1993.306. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Volm M., Drings P., Wodrich W. Prognostic significance of the expression of c-fos, c-jun and c-erbB-1 oncogene products in human squamous cell lung carcinomas. J Cancer Res Clin Oncol. 1993;119(9):507–510. doi: 10.1007/BF01686458. [DOI] [PubMed] [Google Scholar]
  34. Volm M., Efferth T., Mattern J. Oncoprotein (c-myc, c-erbB1, c-erbB2, c-fos) and suppressor gene product (p53) expression in squamous cell carcinomas of the lung. Clinical and biological correlations. Anticancer Res. 1992 Jan-Feb;12(1):11–20. [PubMed] [Google Scholar]
  35. Volm M., Mattern J. Correlation between successful heterotransplantation of lung tumors in nude mice, poor prognosis of patients and expression of Fos, Jun, ErbB1, and Ras. Anticancer Res. 1993 Nov-Dec;13(6A):2021–2025. [PubMed] [Google Scholar]
  36. Waterfield M. D., Mayes E. L., Stroobant P., Bennet P. L., Young S., Goodfellow P. N., Banting G. S., Ozanne B. A monoclonal antibody to the human epidermal growth factor receptor. J Cell Biochem. 1982;20(2):149–161. doi: 10.1002/jcb.240200207. [DOI] [PubMed] [Google Scholar]
  37. Weiner D. B., Nordberg J., Robinson R., Nowell P. C., Gazdar A., Greene M. I., Williams W. V., Cohen J. A., Kern J. A. Expression of the neu gene-encoded protein (P185neu) in human non-small cell carcinomas of the lung. Cancer Res. 1990 Jan 15;50(2):421–425. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES